STRO - NASDAQ
Sutro Biopharma, Inc.
$24.43
+17%Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
At a Glance
Live Snapshotstro
Total Non-Current Assets
Last Annual Value
22.90M
3-Year CAGR
-25%
5-Year CAGR
8%
10-Year CAGR
2%
Sutro Biopharma, Inc. Competitors Analysis of Total Non-Current Assets
| Company | Total Non-Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Sutro Biopharma, Inc. NASDAQ:STRO | 22.90M | -22.5% | -28.5% | 1.6% | |
 Fractyl Health, Inc. Common Stock NASDAQ:GUTS | 33.83M | -5.9% | 40.6% | N/A | |
 Metagenomi, Inc. Common Stock NASDAQ:MGX | 55.56M | -13.7% | 10.9% | N/A | |
 Shattuck Labs, Inc. NASDAQ:STTK | 8.55M | -19.4% | -3.7% | N/A | |
 Pliant Therapeutics, Inc. NASDAQ:PLRX | 28.78M | 62.9% | 19.6% | N/A | |
 Aligos Therapeutics, Inc. NASDAQ:ALGS | 5.67M | -18.4% | -28.8% | N/A | |
 BeyondSpring Inc. NASDAQ:BYSI | 5.05M | -7.5% | -5.0% | 38.0% | |
 CAMP4 Therapeutics Corporation NASDAQ:CAMP | 3.71M | -37.1% | -55.3% | -32.9% | |
 Clene Inc. NASDAQ:CLNN | 9.15M | -12.1% | 1.5% | N/A | |
 NRx Pharmaceuticals, Inc. NASDAQ:NRXP | 4.06M | 111.3% | 206.6% | N/A | |
 Relmada Therapeutics, Inc. NASDAQ:RLMD | 19.50K | -23.2% | -7.2% | -25.3% |
Sutro Biopharma, Inc. Fair Value Envelope
Related Guides
Continue your STRO research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.